Acuta Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Acuta Capital Partners's FDMT Position: Q3 2026 in Review
Acuta Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 5.4% in Q3 2026, buying an estimated $355K and bringing the position to 535,109 shares worth $7.66M. The position accounts for 5.82% of the portfolio, ranked #4.
Acuta Capital Partners first reported a position in FDMT in Q4 2020 and has held it in 6 quarters since. 166 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Acuta Capital Partners held 535,109 shares of 4D Molecular Therapeutics worth $7.66M as of Q3 2026.
- Acuta Capital Partners bought 27,308 4D Molecular Therapeutics shares in Q3 2026, an estimated $355K.
- 4D Molecular Therapeutics made up 5.82% of Acuta Capital Partners's portfolio in Q3 2026, its #4 holding.
- Acuta Capital Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 6 quarters since.
- 166 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.